Stifel raised the firm’s price target on Trupanion to $40 from $30 and keeps a Hold rating on the shares. Over the last twelve months, Trupanion has “solidly right-sized its MLR,” strengthened the balance sheet and kept retention “respectable” when considering the large price increases that have been taken, says the analyst. While the bear case of a dilutive raise, which the firm “never bought into,” has subsided and shares have rallied off lows, the “hard-work may just be starting,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRUP:
- Trupanion price target raised to $56 from $47 at BofA
- Trupanion price target raised to $45 from $35 at Northland
- truInsights into Anxiety in Pets: Trupanion Sees Record High Year of Anxiety Claims, Offers Tips for How to Spot and Prevent
- Trupanion Launches Signature Medical Insurance Product in Europe
- Trupanion launches medical insurance product in Germany, Switzerland